Deepcell

Deepcell is a biotechnology company founded in 2017 as a spinout from Stanford University. The company focuses on advancing precision medicine through innovative single-cell analysis technologies. By integrating artificial intelligence, microfluidics, and high-resolution optics, Deepcell enables detailed, label-free characterization, classification, and sorting of individual cells based on their morphology. The core technology platform, REM-I, utilizes continuous AI-driven learning to perform high-dimensional, quantitative analysis of single cells. This platform can classify and isolate virtually any cell type, including rare cells, while maintaining cell viability for various applications such as translational research, diagnostics, and therapeutic development. Deepcell offers its services to researchers and clinicians, facilitating hypothesis-free exploration of cellular features without relying on specific molecular markers. Headquartered in Menlo Park, California, Deepcell has raised over $90 million in funding and employs around 100 people. The company reported revenues of approximately $21 million and serves scientists and researchers in biology, translational medicine, diagnostics, and therapeutic development.